The SABV Symposium 2026, together with the EU-SABV Core Group meeting (held on June 25th, 2026), is co-organized by the EU-SABV COST Action (CA24168), the European Initiative to Enhance the Current SABV Policy in Preclinical Biomedical Research, funded by the European Cooperation in Science and Technology (COST). Learn more about the EU-SABV COST Action at action webpage
The SABV Symposium 2026 features 23 lectures by internationally renowned experts from 14 countries, exploring the biological basis of sex differences, their underlying mechanisms, and their significance in health and disease. Particular attention will be given to practical strategies for incorporating biological sex into study design, with a special focus on hormone-sensitive stages of female reproductive life and their links to disease risk.
The SABV Symposium 2026 will be accredited as continuing education for study directors and experimenters by the Federation of Swiss Cantonal Veterinary Officers (VSKT).
University Hospital Zurich
Large lecture hall
NORD 1 D 304
Frauenklinikstrasse 10
8091 Zurich
23 - 24 June 2026
To view the full list of speakers, please download the Preliminary Program of the SABV Symposium 2026 using the link below.
Preliminary Program
McGill University, Canada
University of California, Irvine, USA
University of Galway, Ireland
AstraZeneca, UK
University of Florida, USA
LMU Hospital Munich, Germany
Karolinska Institutet, Sweden
Inserm, Paris-Saclay University, France
Charité, Universitätsmedizin Berlin, Germany
Rijksuniversiteit Groningen, Netherlands
Leiden University Medical Center, Netherlands
Max Planck Institute for Brain Research, Germany
University Hospital Regensburg, Germany
University Medical Center Mainz, Germany
Rijksuniversiteit Groningen, Netherlands
University of Zagreb, Croatia
Faculty of Medicine, University of Belgrade, Serbia
University Hospital Bern, Switzerland
This year’s program explores a broad spectrum of research, ranging from sex differences in brain health, pain, and pharmacology to metabolic, oncological, and respiratory diseases. Additionally, the sessions will highlight female biology across the lifespan and the pivotal role of hormonal influences on systemic health.
The preliminary program is available for download in PDF format below:
Preliminary Program
Registration for the SABV Symposium 2026 is now open! You will automatically receive a confirmation once your registration is complete.
8.1 % Swiss VAT is included in the fee.
Abstract submission is open until May 15, 2026. Please send your abstract as a Word document (.docx) to:
sabvsymposium2026@gmail.com
Abstracts should not exceed 250 words. Use Arial, 11 pt font with single line spacing. Include the full names of all authors, with the presenting author underlined. Provide affiliations for each author (institution, city, and country). The abstract should be structured as follows: Background, Methods, Results, and Conclusions. Figures and tables are not permitted.
Submissions of preliminary data are also welcome, as this is a valuable opportunity to present your work and receive feedback from leading experts in the field.
The SABV Symposium 2026, together with the EU-SABV Core Group meeting (held on June 25th, 2026), is co-organized by the EU-SABV COST Action (CA24168), the European Initiative to Enhance the Current SABV Policy in Preclinical Biomedical Research, funded by the European Cooperation in Science and Technology (COST). Learn more about the EU-SABV COST Action at action webpage
Here you can find out more about previous SABV symposia - the SABV Symposium 2022 and SABV Symposium 2024.
